Global perspective and market positioning of pawnbroking for H&T Group
In this note, we put pawnbroking into a global and historical context: i) the global market is large, ca.$40bn, UK just ca.5%; ii) pawnbroking is widely adopted across a range
In this note, we put pawnbroking into a global and historical context: i) the global market is large, ca.$40bn, UK just ca.5%; ii) pawnbroking is widely adopted across a range
In our April 2024 initiation, we highlighted that Duke Capital plc (LON:DUKE), by optimising the best of equity and debt, aimed to achieve equity-type returns with debt levels of risk. We highlighted
The key messages from ICG Enterprise Trust plc (LON:ICGT)T’s June 2024 shareholder seminar were i) ICGT has a focused and differentiated investment strategy with a dedicated investment team, ii) operating performance remains
The key message from ICG Enterprise Trust plc (LON:ICGT) FY’24 results (to January) is the continued strength of the operating companies, which keep delivering mid-teen EBITDA growth. Despite challenging markets, margins have
Hardman & Co reviewed NB Private Equity Partners Ltd (LON:NBPE) business model in our initiation, Co-investments generating superior performance. We noted the high-secular-growth and downside-resilient investee companies, the value added by GPs, the
Criterium Energy (TSX-V: CEQ) Auctus Advisors analyst note: On Track
City of London Investment Group plc (LON:CLIG) has announced its FUM for 3Q’24. It was a positive quarter, with group FUM rising 5.5%, from $9.58bn to $10.10bn. The largest contribution
Duke Capital plc unique product provides SMEs across diversified sectors with hybrid capital, allowing the existing team to retain control. By optimising the best of equity and debt, the company
Chesnara Plc (LON:CSN) has announced its 2023 results. Positive returns from equity markets and gains from acquisitions in the first half were somewhat offset by adverse changes to operating assumptions in
Tissue Regenix Group PLC (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a